NCT04659733 is a Phase 1 clinical trial of Anlotinib hydrochloride in Sarcoma, sponsored by Yizhuo Zhang.

Who is sponsoring NCT04659733?

NCT04659733 is sponsored by Yizhuo Zhang.

What drugs are being tested in NCT04659733?

Interventions in NCT04659733: Anlotinib hydrochloride.

Is NCT04659733 still recruiting?

NCT04659733 is currently status unknown. Last updated 9 December 2020.

Last reviewed 2020-12-09 · How we verify

NCT04659733

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Status unknown Phase 1 Last updated 9 December 2020

What this trial tests

Phase 1 trial testing Anlotinib hydrochloride in Sarcoma in 36 participants. Status unknown.

Timeline

30 December 2020

Primary endpoint
15 December 2022

30 December 2022

Quick facts

Lead sponsor	Yizhuo Zhang
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	30 December 2020
Primary completion	15 December 2022
Estimated completion	30 December 2022

Drugs / interventions tested

Anlotinib hydrochloride

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Yizhuo Zhang — full company profile →

Who can join

Adults 5 to 18, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose is to observe and evaluate the safety and effectiveness of anlotinib in children with progressive, recurrent, and refractory sarcoma. Pharmacokinetics was also detected.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.
Li S. · · 2021 · cited 60× · PMID 34094958 · DOI 10.3389/fonc.2021.664853
The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors.
Lu S, Hong Y, Chen H, Wu L, et al · · 2022 · cited 5× · PMID 35431969 · DOI 10.3389/fphar.2022.711704
Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial.
Lu S, Que Y, Liu D, Sun F, et al · · 2025 · cited 1× · PMID 40496885 · DOI 10.1016/j.eclinm.2025.103258
Efficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis.
Li Z, Fang P, Shen S, Zhang L, et al · · 2025 · PMID 41395622 · DOI 10.3389/fonc.2025.1703261

Verify or expand the search:

Other trials of Anlotinib hydrochloride

Trials testing the same drug.

NCT06476093 — SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer · NA · recruiting
NCT05193188 — A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma · Phase 2 · unknown
NCT05539118 — Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma · Phase 1, PHASE2 · not yet recruiting
NCT05883085 — A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL · Phase 2 · unknown
NCT04952493 — Anlotinib or Penpulimab in Combination With RAI for DTC · Phase 2 · unknown

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Yizhuo Zhang trials

Trials by the same sponsor.

NCT06710821 — Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors · Phase 1 · not yet recruiting
NCT06514313 — Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. · Phase 2 · recruiting
NCT06451302 — Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study · NA · active not recruiting
NCT06208917 — Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compar · Phase 3 · recruiting
NCT05076071 — Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04659733 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yizhuo Zhang
Last refreshed: 9 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing